R
Rudolf Steininger
Researcher at Medical University of Vienna
Publications - 126
Citations - 4271
Rudolf Steininger is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Transplantation & Liver transplantation. The author has an hindex of 37, co-authored 125 publications receiving 4043 citations. Previous affiliations of Rudolf Steininger include University of Vienna.
Papers
More filters
Journal ArticleDOI
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial
Edward K. Geissler,Andreas A. Schnitzbauer,Andreas A. Schnitzbauer,Carl Zülke,P. Lamby,Andrea Proneth,Christophe Duvoux,Patrizia Burra,Karl-Walter Jauch,Markus Rentsch,Tom M. Ganten,Jan Schmidt,Utz Settmacher,Michael Heise,Michael Heise,Giorgio Rossi,Umberto Cillo,Norman M. Kneteman,René Adam,Bart van Hoek,Philippe Bachellier,Philippe Wolf,Lionel Rostaing,Wolf O. Bechstein,Magnus Rizell,James J. Powell,Ernest Hidalgo,J. Gugenheim,Heiner Wolters,Jens Brockmann,André Roy,Ingrid Mutzbauer,Angela Schlitt,Susanne Beckebaum,Christian Graeb,Silvio Nadalin,Umberto Valente,Victor Sanchez Turrion,Neville V. Jamieson,T. Scholz,Michele Colledan,Fred Fändrich,Thomas Becker,Gunnar Söderdahl,Olivier Chazouillères,Heikki Mäkisalo,Georges-Philippe Pageaux,Rudolf Steininger,Thomas Soliman,Koert P. de Jong,Jacques Pirenne,Raimund Margreiter,Johann Pratschke,Antonio Daniele Pinna,Johann Hauss,Stefan Schreiber,Simone I. Strasser,Jürgen Klempnauer,Roberto Troisi,Sherrie Bhoori,Jan Lerut,Itxarone Bilbao,Christian Klein,Alfred Königsrainer,Darius F. Mirza,Gerd Otto,Vincenzo Mazzaferro,Peter Neuhaus,Hans J. Schlitt +68 more
TL;DR: This trial provides the first high-level evidence base for selecting immunosuppression in LTx recipients with HCC and reveals that low-risk, rather than high- risk, patients benefited most from sirolimus; furthermore, younger recipients (age ⩽60) also benefited, as well siro Limus monotherapy patients.
Journal ArticleDOI
Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production
Markus Peck-Radosavljevic,M. Wichlas,Johannes Zacherl,G. Stiegler,Petra Stohlawetz,Michael Fuchsjäger,A. Kreil,Sylvia Metz-Schimmerl,Simon Panzer,Rudolf Steininger,Ferdinand Mühlbacher,Peter Ferenci,Johann Pidlich,Alfred Gangl +13 more
TL;DR: Low TPO serum levels with low platelet counts and without platelet consumption suggesting low TPO production in end-stage liver disease suggests an increase in the bone marrow production of platelets after transplantation.
Journal ArticleDOI
Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver
Markus Peck-Radosavljevic,Markus Peck-Radosavljevic,Johannes Zacherl,Y.Gloria Meng,Johann Pidlich,Johann Pidlich,Emanuel Lipinski,Emanuel Lipinski,Friedrich Längle,Rudolf Steininger,Ferdinand Mühlbacher,Alfred Gangl +11 more
TL;DR: Thrombocytopenia associated with liver disease may at least in part be attributable to inadequate thrombopoietin production in the failing liver.
Journal ArticleDOI
Current value of intraoperative sonography during surgery for hepatic neoplasms
Johannes Zacherl,Christian Scheuba,M. Imhof,Maximilian Zacherl,Friedrich Längle,Peter Pokieser,Fritz Wrba,E. Wenzl,Ferdinand Mühlbacher,Raimund Jakesz,Rudolf Steininger +10 more
TL;DR: It was concluded that IOUS, having undergone some refinement as well, still has immense diagnostic value in hepatectomy candidates and should still be considered the gold standard.
Journal ArticleDOI
A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma
Andreas A. Schnitzbauer,Carl Zuelke,Christian Graeb,Justine Rochon,Itxarone Bilbao,Patrizia Burra,Koert P. de Jong,Christophe Duvoux,Norman M. Kneteman,René Adam,Wolf O. Bechstein,Thomas Becker,Susanne Beckebaum,Olivier Chazouillères,Umberto Cillo,Michele Colledan,Fred Fändrich,Jean Gugenheim,Johann Hauss,Michael Heise,Ernest Hidalgo,Neville V. Jamieson,Alfred Königsrainer,P. Lamby,Jan Lerut,Heikki Mäkisalo,Raimund Margreiter,Vincenzo Mazzaferro,Ingrid Mutzbauer,Gerd Otto,Georges-Philippe Pageaux,Antonio Daniele Pinna,Jacques Pirenne,Magnus Rizell,Giorgio Rossi,Lionel Rostaing,André Roy,Victor Sanchez Turrion,Jan Schmidt,Roberto Troisi,Bart van Hoek,Umberto Valente,Philippe Wolf,Heiner Wolters,Darius F. Mirza,T. Scholz,Rudolf Steininger,Gunnar Söderdahl,Simone I. Strasser,Karl-Walter Jauch,Peter Neuhaus,Hans J. Schlitt,Edward K Geissler +52 more
TL;DR: If the hypothesis is correct that mTOR inhibition can reduce HCC tumour growth while simultaneously providing immunosuppression to protect the liver allograft from rejection, patients should experience less post-transplant problems with HCC recurrence, and therefore could expect a longer and better quality of life.